Vita Coco has lifted its sales and earnings targets after a bumper quarter.
The US-based coconut-water business saw sales jump in its third quarter, boosted by M&A but also organic growth.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Vita Coco’s net sales grew 34% in the three months to 30 September to $244m.
The company said its sales were supported by its acquisition of fellow coconut waters firm Copra earlier this year.
However, Vita Coco reported an 18% increase in its organic sales. Case-equivalent volumes of its namesake brand rose 16%.
The group upped its net-sales target in July after its second-quarter sales grew 28%.
Yesterday (22 October), Vita Coco issued a new forecast for its full-year net sales. The company sees its net sales reaching $810-820m in 2026, up from its earlier forecast of $795-805m.
The top-line growth contributed to improved third-quarter profits. Income from operations reached $45.5m, compared to $27.9m in the third quarter of 2025. Net income increased from $24m to $35m.
Vita Coco provides an earnings metric of adjusted EBITDA, which the company said hit $53m in third quarter, versus $32m a year earlier. It now sees its annual adjusted EBITDA reaching $170-175m, up from its previous forecast of $154-161m.
Co-founder and executive chairman Michael Kirban said: “The growth of the coconut water category maintained through the fall and remains one of the fastest growing beverage categories in our major markets.
“I am particularly pleased by the strong growth in Europe as we develop the category in key markets, and the continued growth in America, driven by increases in both household penetration and in average consumption per household.”
In a note to clients, William Blair analyst Jon Andersen said: “Vita Coco’s updates were solid – with continued healthy category and brand consumption, reasonable margin management in a dynamic cost environment and progress on capacity and Copra – resulting in guidance for sales and EBITDA being raised.
“Our sense is that this 2026 guidance is quite achievable and likely somewhat conservative, as management has consistently underestimated the momentum in the business in recent quarters.”
